Department of Nuclear Medicine, Chongqing University Cancer Hospital, Chongqing, China.
Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, China.
Drug Deliv. 2023 Dec;30(1):2168791. doi: 10.1080/10717544.2023.2168791.
The clinical diagnosis and treatment of malignant bone tumors are still major clinical challenges due to their high incidence are difficulty. Targeted therapies have become a critical approach to treat bone tumors. In recent years, radiopharmaceuticals have been used widely and have shown potent and efficient results in treating bone tumors, among which P and the labeled radiopharmaceuticals play an essential role. In this study, the P-labeled hydroxyapatite (HA) was prepared through chemical synthesis (P-Hap) and physical adsorption (P-doped-Hap). The in vitro stability of P-labeled HA was analyzed to assess the superiority of the new-found chemical synthesis. The radiolabeling yield and stability of chemical synthesis (97.6 ± 0.5%) were significantly improved compared with physical adsorption (92.7 ± 0.4%). Furthermore, the CT results corroborate that P-Hap (100 μCi) +DOX group has the highest tumor suppression rate and can effectively reduce bone destruction. The results corroborate the effectiveness of the chemical synthesis and validate the application of P-Hap in bone tumors. Therefore, P-Hap (100 μCi) + DOX may be an effective strategy for bone metastasis treatments.
由于恶性骨肿瘤的发病率高且治疗难度大，其临床诊断和治疗仍然是主要的临床挑战。靶向治疗已成为治疗骨肿瘤的重要方法。近年来，放射性药物在治疗骨肿瘤方面得到了广泛应用，并且显示出强大而有效的效果，其中 P 和标记的放射性药物发挥着重要作用。在这项研究中，通过化学合成（P-Hap）和物理吸附（P 掺杂-Hap）制备了 P 标记的羟基磷灰石（HA）。分析了 P 标记 HA 的体外稳定性，以评估新发现的化学合成的优越性。与物理吸附（92.7 ± 0.4%）相比，化学合成的放射性标记产率和稳定性（97.6 ± 0.5%）得到了显著提高。此外，CT 结果证实 P-Hap（100 μCi）+DOX 组具有最高的肿瘤抑制率，可以有效减少骨破坏。结果证实了化学合成的有效性，并验证了 P-Hap 在骨肿瘤中的应用。因此，P-Hap（100 μCi）+DOX 可能是治疗骨转移的有效策略。
